← Back to Search

Other

IkT-148009 for Parkinson's Disease

Phase 2
Waitlist Available
Led By Milton Werner, PhD
Research Sponsored by Inhibikase Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants diagnosed with PD consistent with UK Brain Bank criteria and MDS Research Criteria; must include bradykinesia with sequence effect and motor asymmetry
Receiving no anti-parkinsonian therapy
Must not have
Evidence of advanced, age-related macular degeneration or intermediate macular degeneration as defined by Beckman classification
Clinically significant orthostatic hypotension
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to week 12

Summary

This trial tests the safety and effects of IkT-148009, a daily pill, in people aged 30 to 80 with untreated Parkinson's disease. The drug aims to block an enzyme that may help manage symptoms. Participants will take the drug for a few months.

Who is the study for?
This trial is for people aged 30-80 with untreated Parkinson's Disease (PD) who meet specific medical criteria and can self-administer a drug daily with food. They must not need other PD treatments during the study, agree to birth control methods if of childbearing potential, and have no significant health issues that could affect participation.
What is being tested?
The trial tests IkT-148009's safety and how it affects the body compared to a placebo in managing Parkinson's symptoms. Participants will randomly receive either one of three doses of IkT-148009 or a placebo once daily for 12 weeks.
What are the potential side effects?
While specific side effects are not listed here, participants will be monitored for any adverse reactions to IkT-148009 which may include typical drug-related responses such as gastrointestinal discomfort, allergic reactions, or changes in mood or motor function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have Parkinson's disease with slow movements and uneven symptoms on both sides.
Select...
I am not on any medication for Parkinson's disease.
Select...
My Parkinson's disease is in the early or mid-stage.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have advanced or intermediate age-related vision loss.
Select...
I experience significant dizziness when standing up.
Select...
I haven't taken Parkinson's disease medications or supplements for over 28 days.
Select...
I am currently taking medication that strongly affects liver enzymes.
Select...
I have abnormal blood vessel growth in my eye.
Select...
I might have a rare form of Parkinson's disease.
Select...
I have serious kidney problems.
Select...
I have not had thoughts of harming myself in the past year.
Select...
I am currently taking medication for psychosis, nausea, or ADHD.
Select...
I've needed antipsychotics for severe hallucinations in the last year.
Select...
I do not have skin conditions affecting sample collection.
Select...
I have had or am expected to have surgery for Parkinson's disease during the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Clinician Global Impression of Severity (CGI-S)
Complete Spontaneous Bowel Movement (CSBM)
Epworth Sleepiness Scale (ESS)
+9 more
Other study objectives
Phosphorylated alpha-synuclein in cerebrospinal fluid (CSF)
Phosphorylated alpha-synuclein in skin

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: 50mg IkT-148009Experimental Treatment1 Intervention
This arm will consist of thirty (30) patients on 50mg of active treatment.
Group II: 200mg IkT-148009Experimental Treatment1 Intervention
This arm will consist of thirty (30) patients on 200mg of active treatment.
Group III: 100mg IkT-148009Experimental Treatment1 Intervention
This arm will consist of thirty (30) patients on 100mg of active treatment.
Group IV: PlaceboPlacebo Group1 Intervention
This arm will consist of thirty (30) patients on placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IkT-148009
2021
Completed Phase 1
~110

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Parkinson's Disease (PD) primarily aim to increase dopamine levels or mimic its action in the brain, addressing the dopamine deficiency that characterizes the disease. Levodopa, often combined with carbidopa, is converted to dopamine in the brain, providing symptomatic relief. Dopamine agonists, such as pramipexole and ropinirole, directly stimulate dopamine receptors. MAO-B inhibitors, like rasagiline, prevent the breakdown of dopamine, prolonging its action. Amantadine promotes dopamine release and has anticholinergic effects. These treatments are crucial for managing PD symptoms, improving motor function, and enhancing quality of life. The trial of IkT-148009, which evaluates a new treatment's safety and efficacy, is significant as it may offer additional therapeutic options or improvements over existing treatments.
Cannabis and its derivatives for the use of motor symptoms in Parkinson's disease: a systematic review and meta-analysis.Recent developments in the pharmacological treatment of Parkinson's disease.

Find a Location

Who is running the clinical trial?

Inhibikase Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
329 Total Patients Enrolled
Milton Werner, PhDPrincipal InvestigatorInhibikase Therapeutics, Inc.
Sydney KrugerPrincipal InvestigatorInhibikase Therapeutics, Inc.

Media Library

IkT-148009 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05424276 — Phase 2
Parkinson's Disease Research Study Groups: Placebo, 50mg IkT-148009, 100mg IkT-148009, 200mg IkT-148009
Parkinson's Disease Clinical Trial 2023: IkT-148009 Highlights & Side Effects. Trial Name: NCT05424276 — Phase 2
IkT-148009 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05424276 — Phase 2
~46 spots leftby Dec 2025